Excessive activation of the hypothalamicepituitaryeadrenal (HPA) axis has been associated with numerous diseases, including depression, and the tricyclic antidepressant imipramine has been shown to suppress activity of the HPA axis. Central hypothalamic control of the HPA axis is complex and involves a number of neuropeptides released from multiple hypothalamic subnuclei. The present study was therefore designed to determine the effects of imipramine administration on the mouse hypothalamus using a peptidomics approach. Among the factors found to be downregulated after acute (one day) or chronic (21 days) imipramine administration were peptides derived from secretogranin 1 (chromogranin B) as well as peptides derived from cerebellin precursors. In contrast, peptides SRIF-14 and SRIF-28 (1e11) derived from somatostatin (SRIF, somatotropin release inhibiting factor) were significantly upregulated by imipramine in the hypothalamus. Because diminished SRIF levels have long been known to occur in depression, a second part of the study investigated the roles of individual SRIF receptors in mediating potential antidepressant effects. SRA880, an antagonist of the somatostatin-1 autoreceptor (sst1) which positively modulates release of endogenous SRIF, was found to synergize with imipramine in causing antidepressant-like effects in the tail suspension test. Furthermore, chronic co-administration of SRA880 and imipramine synergistically increased BDNF mRNA expression in the cerebral cortex. Application of SRIF or L054264, an sst2 receptor agonist, but not L803807, an sst4 receptor agonist, increased phosphorylation of CaMKII and GluR1 in cerebrocortical slices. Our present experiments thus provide evidence for antidepressant-induced upregulation of SRIF in the brain, and strengthen the notion that augmented SRIF expression and signaling may counter depressive-like symptoms.
t r a c t
Excessive activation of the hypothalamicepituitaryeadrenal (HPA) axis has been associated with numerous diseases, including depression, and the tricyclic antidepressant imipramine has been shown to suppress activity of the HPA axis. Central hypothalamic control of the HPA axis is complex and involves a number of neuropeptides released from multiple hypothalamic subnuclei. The present study was therefore designed to determine the effects of imipramine administration on the mouse hypothalamus using a peptidomics approach. Among the factors found to be downregulated after acute (one day) or chronic (21 days) imipramine administration were peptides derived from secretogranin 1 (chromogranin B) as well as peptides derived from cerebellin precursors. In contrast, peptides SRIF-14 and SRIF-28 (1e11) derived from somatostatin (SRIF, somatotropin release inhibiting factor) were significantly upregulated by imipramine in the hypothalamus. Because diminished SRIF levels have long been known to occur in depression, a second part of the study investigated the roles of individual SRIF receptors in mediating potential antidepressant effects. SRA880, an antagonist of the somatostatin-1 autoreceptor (sst1) which positively modulates release of endogenous SRIF, was found to synergize with imipramine in causing antidepressant-like effects in the tail suspension test. Furthermore, chronic co-administration of SRA880 and imipramine synergistically increased BDNF mRNA expression in the cerebral cortex. Application of SRIF or L054264, an sst2 receptor agonist, but not L803807, an sst4 receptor agonist, increased phosphorylation of CaMKII and GluR1 in cerebrocortical slices. Our present experiments thus provide evidence for antidepressant-induced upregulation of SRIF in the brain, and strengthen the notion that augmented SRIF expression and signaling may counter depressive-like symptoms. This article is part of a Special Issue entitled 'Anxiety and Depression'. Ó 2011 Elsevier Ltd.
Introduction
The hypothalamicepituitaryeadrenal (HPA) axis participates in stress responses and is crucial to the maintenance of homeostasis (Ulrich-Lai and Herman, 2009) . Upon activation of the HPA axis, a hormonal cascade is initiated in the brain, whereby hypothalamic corticotropin-releasing hormone (CRH) induces secretion of adrenocorticotropic hormone (ACTH) from the anterior pituitary gland.
ACTH in turn induces secretion of glucocorticoids (cortisol in humans, corticosterone in rodents) from the cortex of the adrenal glands, the physiological effects of which are extremely diverse. Thus, dysregulation of the HPA axis is associated with a plethora of diseases, and HPA hyperactivation has been convincingly implicated in depression (Chrousos, 2009) . Chronic treatment with the tricyclic antidepressant imipramine suppresses hyperactivity of the HPA axis, as indicated by diminished secretion of ACTH and glucocorticoids in humans and rats (Brady et al., 1991; Butterweck et al., 2001; Frost et al., 2003; Michelson et al., 1997; Shimoda et al., 1988) , which potentially contributes to the antidepressant therapeutic effects of the drug (Michelson et al., 1997) . Evidence available to date suggests that this is mediated centrally at the level of the hypothalamus via inhibition of CRH-containing neurons (Brady et al., 1991; Butterweck et al., 2001; Michelson et al., 1997) .
Central control of the HPA axis is complex and involves multiple neuropeptides produced in multiple hypothalamic nuclei (Herman et al., 2003) . The present study was therefore aimed at investigating the effects of imipramine administration on the mouse hypothalamus using a peptidomics approach. Our goal was to identify and quantify hypothalamic neuropeptides after acute (one day) and chronic (21 days) imipramine administration, a strategy that enables discovery of potentially novel mediators of antidepressant mechanisms. The experiments were designed to include acute and chronic time frames in order to address the delayed therapeutic onset of antidepressant treatment known to occur in human patients.
Materials and methods

Animals
Adult male C57BL/6 (Charles River, Cologne, Germany) and FVB (own breeding at Karolinska Institute of mice originating from a colony at Rockefeller University, New York, USA) mice (25e30 g) were housed in a temperature-and humidity-controlled facility under a 12 h light/dark cycle (lights on at 8:00 AM) in the Department of Pharmacology at Karolinska Institute, Stockholm, Sweden. Standard rodent chow and tap water were provided ad libitum. All procedures were performed according to national and European (86/609/EEC) legislation governing animal experimentation and were approved by a local ethics committee (N211/03). We made every effort to minimize the number of animals used for the study and to avoid any unnecessary distress.
Drugs
Imipramine hydrochloride was obtained from SigmaeAldrich (St. Louis, MO). SRIF-14, L054264 and L803807 were obtained from Tocris Bioscience (Bristol, UK). The somatostatin-1 receptor (sst1) antagonist SRA880 ([3R,4aR,10aR]-1,2,3,4,4a, 5,10,10a-Octahydro-6-methoxy-1-methyl-benz[g]quinoline-3-carboxylic-acid-4-(4-nitro-phenyl)-piperazine-amide, hydrogen malonate) was from the Novartis Institutes for BioMedical Research . Drugs were freshly diluted in 0.9% saline on the day of injection.
Experimental procedures in vivo
2.3.1. Acute and chronic administration of imipramine
In the experiment for subsequent neuropeptidomics analysis, three groups of C57BL/6 mice received intraperitoneal (i.p.) injections of saline or imipramine (10 mg/kg) once per day over the course of three weeks. Two of these groups received saline daily for 20 days and one injection of saline (group "saline") or imipramine (group "acute imipramine") on day 21. The third group received imipramine daily for a total of 21 days (group "chronic imipramine"). To decrease enzymatic protease activities which would degrade normal proteins into peptide fragments and interfere with neuropeptide identifications and quantifications, these animals were sacrificed by focused microwave irradiation and brains were quickly removed from the skull. Samples of hypothalamus were rapidly dissected from the base of the brain using a forceps and stored at À80 C until processing for mass spectrometry.
In another experiment, C57BL/6 animals received 21 days of treatment with either saline or imipramine (10 mg/kg) and were killed by rapid decapitation. Brains were dissected and frozen at À80 C until analysis using in situ hybridization toward Sst mRNA (encoding SRIF) or precursors of secretogranins and cerebellins.
Acute and chronic co-administration of the sst1 antagonist SRA880 and imipramine
To address the effects of the interaction of the sst1 antagonist SRA880 and imipramine on behavioral and neurochemical measures, FVB mice were used. In an acute experiment, FVB mice received a single i.p. injection of saline, imipramine (10 mg/kg), SRA880 (3 mg/kg) or imipramine together with SRA880. In a chronic experiment, mice were treated once per day for 21 days with saline, imipramine (10 mg/kg), SRA880 (3 mg/kg) or imipramine together with SRA880. Mice were either used for behavioral studies, in situ hybridization or brain slice experiments. For in situ hybridization, mice were killed by decapitation, brains were dissected and frozen at À80 C. For brain slice experiments, mice were killed by decapitation, brains were dissected and cortical slices made with a vibratome and incubated in oxygenated artificial cerebrospinal fluid (CSF) (see Section 2.9).
Sample preparation for mass spectrometry
Hypothalamic samples from the three different groups of mice (saline, n ¼ 5; acute imipramine, n ¼ 6; chronic imipramine, n ¼ 6) were extracted and sonicated (Vibra cell 750, Sonics & Materials Inc., Newton, CT, USA) in warm sample buffer (0.25% acetic acid/H 2 O, 0.2 mg tissue/ml) and then further denatured in a heating block for 1 min. Cell debris were spun down for 45 min at 21,000 Â g. The supernatant was transferred to a microfilter device with a cut-off limit of 10 kDa (Microcon YM-10, Millipore, Bedford, MA, USA) and centrifuged for 45 min at 14,000 Â g. The peptide containing fraction was stored at À80 C until analysis.
Mass spectrometry differential display analysis
The peptide samples were randomized and analyzed on reversed phase nl/minflow liquid chromatography (nano-LC; Ettan MDLC, GE Healthcare, Uppsala, Sweden) electrospray ionization (ESI) quadrupole time-of-flight mass spectrometry (Q-Tof MS; Q-Tof2, Waters, Manchester, UK). Briefly, 5 ml of each sample were desalted on a trap column (1.0 mm i.d. Â 5 mm, packed with C18 PepMap100, 5 mm, 100 Å, LC Packings, Amsterdam, the Netherlands) and separated on a nano column (75 mm i.d. Â 15 cm, packed with C18 PepMap100, 3 mm, 100 Å, LC Packings) during a 40 min gradient from 3% to 60% Buffer B (Buffer A: 0.25% acetic acid in water, Buffer B: 84% ACN, 0.25% acetic acid in water) at an approximate flow of 170 nl/min.
Mass spectra were collected in the mass-to-charge ratio (m/z) range of 300e1000 with a mass resolution of 6800 at m/z 544.99 Da (z ¼ 3). The raw MS data were imported into DeCyder MS2.0 (GE Healthcare, Uppsala, Sweden) and aligned and processed using the import and batch module. Peptide masses were automatically detected using parameters such as elution time (0.8 min), typical peak resolution (5000), accepted charge states (between 1 and 10), and background subtracted quantification. Manual verification of the peptides was performed and some peptides were removed or added manually in the PepDetect module. All the files were then aligned and matched in the PepMatch module allowing for elution time to differ up to 1 min and total mass to differ by 0.2 Da.
The peptide intensity maps were normalized using the DeCyderMS embedded function of total intensity distribution normalization (Kaplan et al., 2007) . A filtering criterion which only included peptides present in at least four samples in each group was applied to the dataset. Differences between group means for the extracted peptide data were analyzed by one-way analysis of variance (ANOVA) (GraphPad, GraphPad Software Inc, San Diego, USA) followed by NewmaneKeuls test (pairwise comparisons of groups), with significance set to p < 0.05.
Mass spectrometry identification of peptides
Peptide identification was performed using either nano-LC ESI linear trap quadrupole (LTQ) tandem MS (MS/MS) or nano-LC ESI LTQ Fourier Transform Ion Cyclotron Resonance (FTICR) MS/MS (Thermo Electron, San Jose, CA, USA). The LC configuration was as described above. Data were collected on the LTQ using a method containing three scan events, repeatedly. First a MS scan in the m/z range 300e2000, followed by a zoom scan of the most intense ion and MS/MS scan of the same ion. A chosen peak was allowed to be selected twice before it was put on an exclusion list for 150 s. The FTICR method consisted of five scanning events performed repeatedly. First a MS scan between m/z 200 and 1500 followed by electroncapture dissociation and collision-induced dissociation of the most intense and the second most intense ion. A chosen ion peak was then put on an exclusion list for 60 s.
The tandem MS data were converted into dta files using Xcalibur (version 2.0 SR2) and the dta files were then combined into mgf files using an in-house developed script. Tandem mass spectra were assigned sequences by searching against two targeted sequence collections, namely SwePep precursors and SwePep peptides , using Mascot. These targeted sequence collections have been developed using the SwePep database and provide fast, specific, and sensitive identification of endogenous peptides .
The SwePep precursor and the SwePep peptide sequence collections were searched using unspecific cleavage and a peptide mass tolerance of AE1.5 Da and a fragment mass tolerance of AE0.7 Da. The dataset was searched both with and without a number of possible posttranslational modifications (N-terminal acetylation, N-terminal pyroglutamic acid of glutamine and glutamic acid, C-terminal amidation, deamidation of asparagine and glutamine, phosphorylation, and oxidation). Peptides identified with a score above the significance cut-off (p < 0.05) obtained from Mascot were collected. The false-positive rate was estimated by searching the reversed sequence collections, calculating the number of hits over a threshold, and dividing this number by the number of matches from the targeted sequence collection search. If the false-positive rate was over 1% the threshold was adjusted for that sequence collection.
For identification of peptide sequences not present in the targeted sequence collections the tandem MS data was also searched against UniProt (48.8) (Mus musculus, unspecific cleavage). Additional endogenous peptides were identified by mass matching of FTICR MS data to theoretical masses of endogenous peptides present in SwePep. The quality of the samples was established by these searches validating the presence/absence of the post-mortem degradation marker Stathmin (2e20) .
Behavioral tests
For the tail suspension test (TST), mice were individually suspended by the tail from a horizontal bar (distance from floor was 35 cm) using adhesive tape (distance from tip of tail was 2 cm). Typically, mice demonstrated several escape-oriented behaviors interspersed with temporally increasing bouts of immobility. A 6-min test session was videotaped and subsequently scored by an observer unaware of treatment group. The scored parameter was the number of seconds spent immobile. The open field test (OF) was used to assess locomotor activity, and mice previously used in the TST were allowed at least one week of recovery before OF testing was carried out. Four identical square open field arenas (outside size: 650 Â 650 Â 325 mm; inside size: 500 Â 500 Â 225 mm) were used. The arenas were equipped with two rows of photocells, sensitive to infrared light, placed 20 mm and 50 mm above the floor. Photocells were spaced 31 mm apart, and the last photocell in a row was spaced 17.5 mm from the wall. The open field was enclosed in a ventilated, sound-attenuated box (Kungsbacka Mät och Reglerteknik AB, Fjärås, Sweden). Photocell beam interruptions were automatically recorded and scored (activity count) on a computer. In both the tail suspension and open field paradigm, mice were tested 15 min after injection. Differences between group means were analyzed by one-way analysis of variance (ANOVA) (GraphPad) followed by NewmaneKeuls test (pairwise comparisons of groups).
In situ hybridization
Frozen mouse brains were cut with a cryotome (Leica Microsystems AB, Kista, Sweden) at 12 mm thickness and mounted on poly-L-lysine coated slides. Brain subregions were identified with a brain atlas (Paxinos and Franklin, 2001) . In situ hybridization with synthetic oligodeoxynucleotides (Cybergene AB, Stockholm, Sweden) or complementary RNA probes was carried out as previously described (Svenningsson et al., 1995 . The following oligodeoxynucleotide probes were used for secretogranin precursors (Scg1e3) and cerebellin precursors (Cbln1, 2, 4): Scg1, 5 0 -CTACCTCTCGGCTGTGTCCTCCTCCTTCTCCACTTC-3 0 ; Scg2, 5 0 -ACTCTCTCTCC GGTTTTCTTCATCTGGGAGCCCCAACTGCCC-3 0 ; Scg3, 5 0 -CCAAGAGCCGGTCCAAAGG AACCCCATTCTTTCTTGCTT-3 0 ; Cbln1, 5 0 -AGTCAAACCAGTCACCACGAAGGTGAGTCTTT CCTTCGCTAACAA-3 0 ; Cbln2, 5 0 -CAATGCCCAGCTCCCTCCCAAGACCCCCAAGACCCTAG GGAAAAGC-3 0 ; Cbln4, 5 0 -AGGGGAAGATGATGATCCCTTGGAGTCTGTAGCTGGGTTCG AGTCG-3 0 . Oligodeoxynucleotide probes were radiolabeled using terminal deoxynucleotidyl transferase (GE Healthcare, Uppsala, Sweden) and 35 S-dATP (Du Pont, New England Nuclear, Stockholm, Sweden) to a specific activity of about to 10 7 cpm/pg. Sections were hybridized in a cocktail containing 50% deionized formamide (Fluka, Buchs, Switzerland), 4Â SSC, 1Â Denhardt's solution, 1% sarcosyl, 0.02 M sodium pyrophosphate (Na 4 P 2 O 7 ; pH 7.0), 10% dextran sulfate, 0.5 mg/ml yeast tRNA (Sigma, Stockholm, Sweden), 0.06 M dithiothreitol, 0.1 mg/ml sheared salmon sperm DNA, and 10 6 cpm/ml of probe. After hybridization for 15 h at 42 C, the sections were washed four times, for 15 min each, in 1Â sodium chlorideesodium citrate buffer (SSC) at 55 C. Sections were subsequently briefly dipped in water, dehydrated through 70%, 95% and 99.5% ethanol, and finally air-dried. Sections were apposed to Kodak MR film for 3e5 weeks and films were manually developed (Kodak D19, Unifix). Autoradiograms were digitized using a scanner (Epson Perfection 4870 PHOTO) and densitometric quantification was carried out using Scion Image for Windows (alfa 4.0.3.2, Scion Corporation). Differences between group means were analyzed by one-way analysis of variance (ANOVA) (GraphPad Prism) followed by NewmaneKeuls test. Analyses of BDNF and Sst mRNAs expression were carried out using complementary RNA probes covering coding regions of BDNF (500 bp; amino acids 1e166 of proBDNF) or Sst (213 bp; amino acids 44e115 of proSRIF), respectively. The BDNF probe was a kind gift of Drs Michael Saxe and Rene Hen, Columbia University, New York, USA. The probes were labeled with 35 S-UTP and used for riboprobe in situ hybridization.
Preparation and incubation of cortical brain slices for phosphorylation experiments
Mouse brains were rapidly removed and placed in ice-cold, oxygenated (95% O 2 þ 5% CO 2 ) artificial cerebrospinal fluid (aCSF) containing (in mM): 126 NaCl, 2.5 KCl, 1.2 NaH 2 PO 4 , 1.3 MgCl 2 , 2.4 CaCl 2 , 10 glucose and 26 NaHCO 3 , pH 7.4. Coronal slices (300 mm thick) were prepared using a Leica vibratome (Leica, Germany).
Cortices were dissected from the slices in ice-cold aCSF buffer. Each slice was placed in a polypropylene incubation tube with 2 ml of fresh aCSF buffer. The slices were preincubated at 30 C under constant oxygenation (95% O 2 /5% CO 2 ) for 60 min with a change of buffer after 30 min. The buffer was then replaced with fresh aCSF and slices were treated with SRIF-14, L054264 or L803807 (1 mM; Tocris) for 5 min. After drug treatment, the samples were frozen on dry ice and stored at À80 C until assayed.
Immunoblotting
Frozen tissue samples were sonicated in 1% SDS, transferred to Eppendorf tubes and boiled for additional 10 min. Small aliquots of the homogenate were retained for protein determination by the BCA protein assay method (Pierce, Rockford, IL, USA) using bovine serum albumin as a standard. Equal amounts of protein (20 mg) were loaded onto 12% acrylamide gels, and the proteins were separated by SDSePAGE and transferred to Immobilion-P transfer membranes (0.2 mm) (Millipore, Solna, Sweden). The membranes were immunoblotted using P-Ser crossreactive bands of a slightly higher molecular weight were found. This has been observed previously in other studies (Snyder et al., 2000) , and only the lower specific bands of the expected molecular weights were quantified.
Data analysis and statistics
Autoradiograms from the in situ hybridization and western blotting experiments were digitized using a Dia-Scanner (Epson Perfection 4870 PHOTO). Optical density values were measured using Scion Image for Windows (Beta 4.0.2 Ó 2000 Scion Corporation). Data were analyzed with Student's t-test, one-way ANOVA or two-way ANOVA followed by pairwise comparisons, as indicated.
Results
Detected and identified peptides
An average of 466 AE 72 peptides was automatically detected in each sample of the nano-LC MS profiles using DeCyderMS. Following manual curation, the number of detected peptides was reduced to 408 AE 45. All profiles were matched using the PepMatch module, yielding 201 peaks present in all samples. Filtering for peaks present in at least four samples per treatment group yielded 273 peaks. The total intensity distribution normalization reduced the median coefficient of variance for the detected peaks present in all profiles by 17%.
In total, 78 hypothalamic peptides were identified from 24 different precursors (Supplementary Table 1 ). Of these, 64 were identified by tandem MS data and database searches. An additional 14 peptides were suggested by mass matching of FTICR MS data against theoretical masses of endogenous peptides present in SwePep. Several of the detected peptides are known to have biological functions, such as Met-enkephalin, Leu-enkephalin, substance P, melanotropin alpha, and Arg-CLIP, while others represent previously uncharacterized species derived from known neuropeptide precursors. Many display characteristic neuropeptide cleavage sites and some carry posttranslational modifications that may indicate biological activity. Examples of the latter include the C-terminally amidated peptide AEEEAVWGDGSPEPSPRE derived from the corticotropinelipotropin precursor, or the secretogranin 1-derived peptide QKIAEKFSQ, posttranslationally modified by N-terminal pyroglutamic acid. The quality marker stathmin (2e20) was not identified in the hypothalamic samples from our present study, hence they were considered to be of good quality with respect to post-mortem degradation .
Peptides differentially regulated by imipramine administration
Statistical analysis revealed fourteen peptides that were significantly regulated according to ANOVA (see Supplementary Table 1 for all details). Four of these derive from the secretogranin 1 precursor (Fig. 1 , top panel; SEESQEREY: F 2,14 ¼ 3.94, p < 0.05; SFARAPQLD: F 2,14 ¼ 6.02, p < 0.05; LLDEGHYPVRESPIDTA: F 2,14 ¼ 6.38, p < 0.05; LLDEGHYPV: F 2,14 ¼ 6.60, p < 0.05) and were downregulated (30e62%) following chronic administration of imipramine compared to saline controls. There was a similar tendency for downregulation in mice treated acutely with imipramine, but this reached significance only for the peptide SFAR-APQLD. Six differentially regulated peptides in the present dataset Fig. 1 . Regulation of hypothalamic neuropeptides by imipramine administration to C57BL/6 mice. Peptide ion intensities are expressed as mean log2 intensities AE SEM (n ¼ 5e6). The sequences of peptides derived from secretogranin 1, cerebellins 1, 2 and 4, as well as somatostatin (SRIF) are given above the respective graphs. Differences between groups were analyzed by one-way ANOVA followed by NewmaneKeuls test for pairwise comparisons (different from saline: *p < 0.05, **p < 0.01; different from chronic imipramine: # p < 0.05; see Supplementary Table 1 for all statistical details).
A. Nilsson et al. / Neuropharmacology 62 (2012) 347e357 derive from three different cerebellin precursors (Fig. 1, middle F 2,14 ¼ 7.68, p < 0.01). The peptides SGSAKVAFSAIRSTNH and GSAKVAFSAIRSTNH are annotated in UniProtKB as cerebellin and des-Ser1-cerebellin, respectively. The peptides from cerebellin 2 and cerebellin 4 identified here correspond to sequences homologous to cerebellin 1. The three cerebellin 1-derived peptides (Fig. 1 , middle panel) were downregulated following acute (35e46%) and chronic (40e54%) imipramine administration. This pattern of regulation was similar for the cerebellin 4-derived peptides. Thus, SKVAFSAVRSTN was downregulated 27% (acute) and 21% (chronic), while the longer form AANSKVAFSAVRSTN was downregulated 30% following acute imipramine administration (Fig. 1, lower panel) . The cerebellin 2-derived peptide SGSAKVAFSATRSTNH was also downregulated 40% following acute imipramine, but its abundance almost returned to control levels following chronic administration (Fig. 1, middle panel) .
Expression of two peptides derived from the somatostatin (SRIF) precursor was also regulated by imipramine administration (Fig. 1 , lower panel; SANSNPAMAPR: F 2,14 ¼ 4.20, p < 0.05; AGCKNFF WKTFTSC: F 2,14 ¼ 4.07, p < 0.05). Abundance of the peptide SANSNPAMAPR [SRIF-28 (1e11)] was found to be increased 75% in hypothalamus of mice chronically treated with imipramine. Peptide AGCKNFFWKTFTSC (SRIF-14) displayed a similar pattern with an upregulation of 150%. This peptide was however only identified by mass matching (mass accuracy 0.5 ppm). It is annotated to contain a disulfide bridge which might contribute to the lack of identity verification by MS/MS data.
GAGENLGGSAVDDPAPLT, corresponding to the C-terminal part of PACAP-related peptide (PRP), was regulated in the hypothalamus (F 2,14 ¼ 3.77, p < 0.05) and found to be increased 70% by chronic imipramine administration (Supplementary Table 1 ). Finally, a phosphorylated fragment derived from the neuroendocrine protein 7B2 was regulated (SVPHFSEEEKEAE þ Phospho: F 2,13 ¼ 9.35, p < 0.01) and found to be decreased 30% following chronic imipramine administration. The unphosphorylated form of this peptide was also identified in the hypothalamic samples, expression levels of which were unaffected by treatment (Supplementary Table 1 ).
In situ hybridization analysis of neuropeptide gene expression after imipramine administration
To assess whether altered neuropeptide expression after imipramine administration is paralleled by changes in expression of the corresponding transcripts, in situ hybridization experiments were carried out. Neither acute nor chronic administration of imipramine had significant effects on the expression of secretogranin precursor transcripts 1 and 3 (Fig. 2) , suggesting that changes in abundance of the respective peptides occur at the posttranscriptional level. Conversely, while no regulation of secretogranin 2-derived peptides was found (Supplementary Table 1) , chronic imipramine administration caused a significant increase in secretogranin 2 mRNA expression in the hypothalamus ( Fig. 2; 
A recent report (Miura et al., 2006) provided a comprehensive analysis of cerebellin mRNA expression in the mouse brain. In the present study, we verified that transcripts encoding cerebellin 1, 2 and 4 are expressed in mouse hypothalamus. Chronic administration of imipramine caused a consistent downregulation not only of cerebellin 1-derived peptides ( Fig. 1 ) but also of cerebellin 1 mRNA ( Fig. 2 ; t ¼ 3.74, df ¼ 6, p < 0.01), suggesting that imipramine may regulate cerebellin 1 expression via a mechanism involving gene transcription. Such regulation may be specific to cerebellin 1, since chronic imipramine administration reduced peptide abundance ( Fig. 1) but did not change transcript expression (Fig. 2) of cerebellin 2 and 4.
Abundance of Sst, the transcript encoding SRIF, was not statistically significantly affected by chronic imipramine administration (Fig. 2) . Thus, upregulation of SRIF-derived peptides (Fig. 1) seems to occur through a posttranscriptional mechanism.
Behavioral effects of co-administration of imipramine and SRA880
Having found imipramine-induced upregulation of SRIF peptides in the hypothalamus, we asked whether blockade of the Fig. 2 . Regulation of neuropeptide transcripts in the hypothalamus of C57BL/6 mice by imipramine administration. Results from in situ hybridization (ISH) were quantified by densitometry and are expressed as percentages relative to corresponding saline-treated controls (mean AE SEM; n ¼ 3e5 mice per group). Effects of chronic imipramine administration were compared to saline-treated controls and analyzed by unpaired t-test (*p < 0.05, **p < 0.01). Imipramine significantly increased expression of Scg2 (t ¼ 3.58, df ¼ 5) and downregulated Cbln1 (t ¼ 3.74, df ¼ 6). Representative ISH autoradiograms from saline-treated mice are shown above the corresponding graphs. sst1 autoreceptor (i.e. disinhibition of endogenous SRIF signaling) would potentiate antidepressant-like behavior elicited by imipramine in the tail suspension test (TST). In an experiment with C57BL/6 mice, acute administration of imipramine strongly reduced immobility time by 45% (data not shown). Administration of SRA880 had no effect on its own and did not alter the aforementioned response to imipramine. As has been reported earlier (Mayorga and Lucki, 2001 ), several of the C57BL/6 mice (12%; data not shown) climbed up their own tail during the TST. The profound reduction of immobility time after acute imipramine administration (potential ceiling effect) and the tail climbing phenomenon seen in C57BL/6 mice (potential exclusion of numerous subjects from analysis) prompted us to use the FVB strain for this part of the study instead. Mice from this strain have not been reported to climb their tail, thus making them better suited for the TST procedure. Furthermore, their response to imipramine is moderate, leading to reductions of immobility time around 20% (Liu and Gershenfeld, 2003) . In FVB mice, none of the acute treatments during our study affected immobility time in the TST (Fig. 3) , whereas results differed between treatment groups in the chronic experiment according to one-way ANOVA (F 3,33 ¼ 5.55, p < 0.01). Chronic administration of imipramine alone reduced immobility almost 20%, although this did not reach statistical significance. Strikingly, SRA880 potentiated this effect of imipramine during chronic coadministration, leading to a significant 40% decrease in immobility time compared to saline-treated mice (NewmaneKeuls test for pairwise comparisons, p < 0.01). Animals chronically treated with SRA880 alone were indistinguishable from saline controls (Fig. 3) . Antidepressant-like effects of combined administration of imipramine and SRA880 were not due to stimulation of locomotor activity, as there were no significant differences between any of the four chronic treatment groups in the open field test (Fig. 3) . No changes in thigmotaxis (i.e. activity in the periphery of the open field divided by the total activity) were found between groups, neither after acute (saline 0.77 AE 0.08; imipramine 0.84 AE 0.10; SRA880 0.73 AE 0.11; imipramine þ SRA880 0.76 AE 0.08) nor chronic (saline 0.71 AE 0.08; SRA880 0.57 AE 0.06; imipramine 0.51 AE 0.07; imipramine þ SRA880 0.61 AE 0.10 ) treatments.
Effects of co-administration of imipramine and SRA880 on gene expression in the brain
The results from our peptidomic and behavioral analyses suggested that imipramine-induced upregulation of SRIF and SRA880-mediated disinhibition of SRIF signaling could synergize in causing antidepressant-like effects. To test whether such synergy also operates at the level of gene expression, we carried out in situ hybridization for BDNF and Sst (encoding SRIF) mRNA in the brain. BDNF is an activity-dependent gene which is upregulated by various chronic antidepressant regimens, and two-way ANOVA revealed a significant main effect of time in our experiments (F 1,42 ¼ 12.93, p < 0.001). Post-hoc comparisons revealed no significant effects of imipramine or SRA880 alone on BDNF. However, imipramine and SRA880 synergized upon chronic coadministration and caused increased BDNF mRNA expression in the cerebral cortex (Table 1 and Fig. 4 ; different from chronic saline, p < 0.05). Effects of treatments did not reach significance in the other brain regions analyzed in the present experiments, and no significant changes in expression of Sst mRNA were found.
Effects of SRIF and selective sst2 or 4 receptor agonists on the phosphorylation states of CaMKII and GluR1 in cortical brain slices
To further explore the mechanisms by which SRIF may regulate activity-dependent processes in cerebral cortex, we studied the effects of SRIF-14 on the phosphorylation states of CaMKII and GluR1 in cortical brain slices from chronically saline-or imipramine-treated mice (Fig. 5) . It was found that SRIF-14 (1 mM) increased P-Thr 286 -CaMKII both in saline and imipramine-treated mice (saline-treated: t ¼ 2.45, df ¼ 10, p < 0.05; imipraminetreated: t ¼ 2.51, df ¼ 10, p < 0.05). SRIF-14 also increased P-Ser 845 -GluR1 (t ¼ 2.84, df ¼ 10, p < 0.05), but not P-Ser 831 -GluR1
(data not shown), in saline-treated mice. Similarly, L054264 (1 mM), an sst2 agonist, increased P-Thr 286 -CaMKII in imipramine-treated mice (t ¼ 2.62, df ¼ 10, p < 0.05) as well as P-Ser 845 -GluR1 (t ¼ 3.01, df ¼ 10, p < 0.05), but not P-Ser 831 -GluR1 (data not shown), in saline-treated mice. In contrast, the sst4 agonist, Fig. 3 . Chronic co-administration of imipramine and the sst1 receptor antagonist SRA880 produces synergistic antidepressant-like behavior in FVB mice. Tail suspension test sessions (6 min) were videotaped and manually scored by a blinded observer. Results are expressed as seconds of immobility time (mean AE SEM; n ¼ 7e10 mice per group). Open field testing (15 min) was carried out using an automated system measuring photocell beam interruptions (activity counts) as an index of locomotion. Results are expressed as group mean AE SEM (n ¼ 7e10 animals per group). Differences between group means were analyzed within the acute and chronic experiments, respectively, by one-way ANOVA (significant differences between tail suspension results in the chronic experiment; F 3,33 ¼ 5.55, p < 0.01) followed by NewmaneKeuls test for pairwise comparisons (different from saline: **p < 0.01; different from chronic imipramine: L803807 (1 mM) had no significant effects on the phosphorylation states of CaMKII and GluR1 in the cortical slices (Fig. 5 ). There were no changes on P-Ser 831 -GluR1 or on the total levels of CaMKII or GluR1 in any of the treatment groups.
Discussion
By performing a "neuropeptidomics" study of the mouse hypothalamus after imipramine administration, the present study was aimed at identifying potentially novel mediators of antidepressant-induced signaling in the brain. More detailed analysis of SRIF, a candidate arising from this discovery approach, contributes evidence to the growing body of literature implicating neuropeptides in the control of stress, anxiety and depression.
Neuropeptidomic analysis of mouse hypothalamus after imipramine administration
Efficient sample preparation Svensson et al., 2003) together with nano-LC MS profiling allows for the simultaneous detection and identification of a great number of peptides. Mass spectrometric analysis provides the ability to differentiate between unique peptides derived from the same precursor, setting it apart from conventional techniques, such as Western blotting or radioimmunoassay, which are limited in multiplexing capability and differentiation of individual peptide species. Furthermore, in conventional assays, the peptides investigated have to be known a priori, whereas our method enables unbiased discovery of novel species. In the present study, we were able to identify and quantify 78 peptides from mouse hypothalamic tissue samples. The use of a sample preparation protocol that includes a quality control for post-mortem degradation and targeted neuropeptide sequence collections increases the quality and peptide identification efficiency of the final analysis. The majority of the peptides identified here were derived from precursors known to yield bioactive fragments, and many were cleaved from sites specific to prohormone convertases . These facts and additional characteristics, such as the presence of posttranslational modifications, speak in favor of such peptides being biologically active, providing a starting point for more detailed investigation.
It should be pointed out that several important hypothalamic neuropeptides were not detected using the method described in the present report, including corticotropin-releasing hormone (CRH), pituitary adenylate cyclase-activating polypeptide (PACAP), vasoactive intestinal peptide (VIP) and galanin. All these peptides are relatively large molecular weight peptides (around 5000 Da) and might not be captured efficiently into the aqueous extraction solution used in our procedure. Furthermore, it is known that some peptides, such as CRH, are prone to adsorb to surfaces or bind to larger proteins (Behan et al., 1995; Kertscher et al., 1998) , hence limiting their passage through the 10 kDa cut-off filter. Vasopressin was identified but found not to be changed after imipramine administration (Supplementary Table 1 ). Full-length somatostatin (SRIF-28), of which SRIF-14 is a fragment, was also not detected in our assay. Nonetheless, the successful identification of several novel candidates, and the functional validation of SRIF-14 as a potential mediator of imipramine-induced antidepressant-like effects (see below), clearly shows the usefulness of our peptidomics approach.
Potential roles of differentially regulated peptides in mediating imipramine-induced effects
Numerous psychiatric conditions, including depression, have been associated with excessive activity of the hypothalamice pituitaryeadrenal (HPA) axis, the cardinal feature of which is Table 1 Effects of co-administration of imipramine and the sst1 receptor antagonist SRA880 on gene expression of BDNF and Sst (SRIF) in the brain of FVB mice. Results from in situ hybridization were quantified by densitometry and expressed as percentages relative to saline-treated controls, each within the acute and chronic experiment (mean AE SEM; n ¼ 6e7 mice per group). Differences were analyzed by two-way ANOVA followed by Bonferroni post-test. A significant effect of time (F 1,42 ¼ 12.93, p < 0.001) was found in the case of BDNF in cortex, and post-hoc analyses showed a significant difference (*p < 0.05) between mice chronically treated with saline and imipramine þ SRA880. DG, dentate gyrus; CA1 -Cornu Ammonis 1; CA3 -Cornu Ammonis 3; Hypo, hypothalamus; imi, imipramine (10 mg/kg); sal, saline; SRA, SRA880 (3 mg/kg). Fig. 4 . Expression of BDNF mRNA in the forebrain after chronic administration of imipramine, SRA880 or a combination of both agents to FVB mice. Representative images from in situ hybridization experiments are shown for cortex and hippocampus (see Table 1 for numerical results from all brain regions).
glucocorticoid hypersecretion (Chrousos, 2009 ). The tricyclic drug imipramine is effective against depression and suppresses the HPA axis (Brady et al., 1991; Butterweck et al., 2001; Frost et al., 2003; Michelson et al., 1997; Shimoda et al., 1988) , which has led to the suggestion that HPA suppression is a component of imipramineinduced therapeutic responses (Michelson et al., 1997) . However, the underlying mechanisms have yet to be elucidated, and additional pathways may exist. In the present study, we provide evidence indicating that antidepressant responses in the brain involve differential regulation of neuropeptides.
4.2.1. Downregulation of secretogranin 1 and cerebellin-derived peptides in the hypothalamus Secretogranin 1 (also called chromogranin B) belongs to the granin family of secretory proteins. These acidic proteins are major components of secretory vesicles and involved in the packaging and release of neurotransmitters and hormones [see (Taupenot et al., 2003) for review]. Several fragments of secretogranin 1 have been described, some of which are biologically active in different tissues (Taupenot et al., 2003) , but there is currently no evidence for these fragments playing a role in hypothalamic function. Of the four secretogranin 1 fragments detected in the present study, three have previously been found in hypothalamic tissue by Dr. L. Fricker's laboratory [see for example (Wardman et al., 2010) ], whereas the peptide SEESQEREY has been described by us (Nilsson et al., 2009) . The fact that all four fragments were found to be downregulated after imipramine administration suggests a regulatory mechanism reducing overall expression of secretogranin 1, which most likely does not proceed via regulation of gene expression, given that Scg1 mRNA was unaffected by chronic imipramine. Additional experiments will be necessary to determine the nature of the regulatory mechanism and its potential consequences.
Peptidomic analysis of the mouse hypothalamus also revealed several peptides from the cerebellin family to be downregulated in response to imipramine treatment. Cerebellin (derived from the cerebellin 1 precursor) was first discovered in the cerebellum and proposed to be a specific marker for this brain region (Slemmon et al., 1984) . It is now known that the genes encoding cerebellins (Cbln1e4) are expressed in many regions of the mouse brain, including the hypothalamus, with the exception of Cbln3 (Miura et al., 2006) . Depolarization-induced, calcium-dependent release from hypothalamic slices indicated that cerebellin is a putative neurotransmitter in the hypothalamus (Burnet et al., 1988) , and recent peptidomic data from the rat suprachiasmatic nucleus suggested a role in circadian rhythms (Lee et al., 2010) , but functional evidence supporting these notions is still lacking. Nonetheless, we found a significant reduction in expression of cerebellin 1 peptide and transcript in response to imipramine administration. Regarding the identification in our study of peptides derived from the cerebellin 1 precursor, it is worth noting that full-length cerebellin (16 amino acids) as well as a shorter form (lacking the final histidine) were previously identified in peptidomic studies of mouse hypothalamus (Che et al., 2007) and rat suprachiasmatic nucleus (Lee et al., 2010) .
Upregulation of SRIF in the hypothalamus e potential effects on stress responses
Our present results show that imipramine significantly induces expression of somatostatin (SRIF) in the mouse hypothalamus. SRIF has long been implicated in disorders of the central nervous system (CNS), including depression, based on the finding that SRIF concentrations in cerebrospinal fluid (CSF) from depressed patients are lower compared to control subjects [see (Bissette and Myers, 1992; Markou et al., 1998) for review]. Previous studies found no -GluR1 and P-Ser 845 -GluR1, crossreactive bands of a slightly higher molecular weight were found. Only the lower specific bands of the expected molecular weights were quantified. Results are expressed as group mean AE SEM (n ¼ 6 slices per treatment group). Differences were analyzed by unpaired t-test (*p < 0.05).
effect of chronic imipramine administration on SRIF concentrations in rat brain (Kakigi et al., 1992) or human CSF (Lepola et al., 1989; Rubinow et al., 1985) , but species (mouse versus rat and human) and assay (present approach versus radioimmunoassay) may account for these differences. Using our peptidomics approach, we detected four peptides derived from the SRIF precursor whose expression was differentially regulated in mouse hypothalamic tissue. Of these, SRIF-14 and SRIF-28 (1e11) were upregulated after chronic imipramine administration, whereas SRIF-28 (1e12) and its oxidized form were unchanged relative to saline-treated control mice. To our knowledge, SRIF-28 (1e11) has only been described as a tryptic fragment of SRIF-28 (Esch et al., 1980; Gluschankof et al., 1985) . Whether it is a degradation product of our assay procedure is not clear at present, since the enzyme responsible for cleaving SRIF-28 into SRIF-14 and -28 (1e12) in the CNS does not generate SRIF-28 (1e11) (Gluschankof et al., 1985) . On the other hand, a significant body of evidence exists regarding the distribution and function of SRIF-14 and SRIF-28 (1e12) in the CNS. Both peptides are released from the hypothalamus and median eminence, with some data suggesting that release is selective (Bakhit et al., 1984) . In addition, both peptides are secreted into hypophyseal portal blood in the rat (Millar et al., 1983; Sheward et al., 1984) . While there is ample and solid evidence for effects of SRIF-14 in the CNS, no physiological role for SRIF-28 (1e12) has been described yet. For example, intracerebroventricular (i.c.v.) infusion of SRIF-14 increases hypothalamic serotonin and dopamine concentrations, facilitates avoidance learning and dose-dependently affects locomotor behavior in rats, while SRIF-28 (1e12) is inactive . Furthermore, neuronal activity in hippocampus and brain stem is modulated by SRIF-14, but unaffected by SRIF-28 (1e12) in vitro (Jacquin et al., 1988; Watson and Pittman, 1988) . Upregulation of SRIF-14 as observed in our present study therefore represents upregulation of a physiologically relevant peptide species.
In vivo, SRIF inhibits stress-induced ACTH secretion without affecting its basal concentrations (Brown et al., 1984; Petraglia et al., 1986) . Since it does not affect ACTH secretion induced by administration of CRH (Brown et al., 1984; Stafford et al., 1989) , it has been hypothesized that the HPA-inhibitory effect of SRIF is mediated centrally via inhibition of CRH release from the hypothalamus (Brown et al., 1984) . According to Brown et al., this effect is elicited by SRIF-28 but not SRIF-14 (Brown et al., 1984) . Of note, CRHinduced ACTH secretion is significantly diminished by the SRIF analog and sst1/2/3/5 receptor agonist SOM230 (Silva et al., 2005) . The bulk of the literature thus supports the notion that SRIF suppresses activity of the HPA axis in the brain specifically during stress responses.
Disinhibition of SRIF signaling in the brain e antidepressantlike effects
In line with its aforementioned inhibitory impact on the HPA axis during stress, SRIF infused into the cerebral ventricles causes antidepressant-and anxiolytic-like effects in rats (Engin et al., 2008) , most likely mediated by the sst2 and sst3 receptor subtypes (Engin and Treit, 2009) . Motivated by these recent reports and our finding that SRIF-14 is upregulated in mouse hypothalamus after imipramine administration, we investigated whether SRIF signaling affects behavioral tests of depressive-like symptoms in mice. For this purpose, we used an antagonist of the sst1 receptor that has recently been shown to increase release of endogenous SRIF-14 in the hippocampus (De Bundel et al., 2010) and nucleus accumbens (Vasilaki et al., 2004) . In other words, we selected a pharmacological agent that e via inhibition of the inhibitory sst1 autoreceptor (Thermos et al., 2006 ) e enhances SRIF signaling in the brain, specifically at those neurons that express and release SRIF endogenously. Our results show that chronic administration of the compound SRA880 synergizes with chronic imipramine in causing antidepressant-like behavior (reduced immobility time) in the tail suspension test, without exerting effects on its own. The tail suspension test is widely used as a model to assess antidepressant-related behavior (Cryan et al., 2005) , however, it should be recognized, that its use is best exploited when used in battery style fashion with other depression models such as learned helplessness, anhedonia models, social defeat and novelty-induced hypophagia. It will be important, in future studies, to study the interaction between SRA880 and imipramine in additional antidepressant-related tests. Nonetheless, our data is in overall agreement with results cited by Weckbecker et al. according to which SRA880 affects behavioral indices of anxiety, depression and bipolar disorder in mice (Weckbecker et al., 2003) , although indices of anxiety (e.g. thigmotaxis in the open field test) were not affected in our studies. Furthermore, our experiments show that chronic co-administration of SRA880 and imipramine elicits a significant increase in BDNF mRNA expression in the cerebral cortex. Given the activity-dependent regulation of BDNF and its role in neuronal plasticity and depression (Duman and Monteggia, 2006) , this finding presents an important lead for future experiments aimed at further elucidating the molecular consequences of combined treatment with imipramine plus SRA880. To start to address this question, we performed experiments in cerebrocortical brain slices from mice chronically treated with saline or imipramine. Because SRA880 disinhibits SRIF release, we mimicked the probable action of SRA880 by applying SRIF directly onto the brain slices. It was found that SRIF increased the phosphorylation states of CaMKII and GluR1, postsynaptic proteins known to regulate neuronal activity, both in slices from saline-and imipraminetreated mice. There is limited data on the impact of SRIF on neuronal activity in cortical circuitry in mice, but experiments from hippocampus have implicated sst2 and sst4 receptors in the regulation of excitatory neurotransmission (Moneta et al., 2002) . Stimulation of sst2 receptors has also been linked to activation of CaMKII in cell lines (Liu and Wong, 2005) . Both sst2 and sst4 receptors are expressed in cortex (Thoss et al., 1995) and we therefore treated slices with agonists selective for these receptor subtypes. It was found that application of an sst2, but not sst4, agonist had similar effects as SRIF on regulating the phosphorylation states of CaMKII and GluR1. Taken together with results from the literature, our data thus support the notion that sst1 functions as an inhibitory autoreceptor whose inhibition (through SRA880) enables induced SRIF release to stimulate postsynaptic sst2 receptors. Fig. 6 provides a schematic summary of the pathway proposed on the basis of previous results and our present study. Recent data indicate that the sst1 receptor itself may be upregulated in the hippocampal CA1 region after treatment with desipramine, an antidepressant drug and active metabolite of imipramine (Pallis et al., 2009) . In the present study, we found no change in Sst mRNA (encoding SRIF) in the hippocampus, and more work is needed to fully characterize the plasticity of the SRIF system in response to antidepressants.
In conclusion, our present report provides an example of how neuropeptidomics can be used as a powerful approach to discovering mediators of antidepressant action in the brain. The most prominent candidate emerging from our experiments is SRIF, a peptide long implicated in psychiatric diseases, and its functional validation in a rodent test of depressive-like behavior yields novel clues as to how SRIF signaling may be employed to counter depressive symptoms in humans.
